Biogen’s multiple sclerosis drug Plegridy gets FDA approval
The company said that Plegridy is the only pegylated beta interferon approved to use in RMS, which is dosed once every two weeks. The drug can be administered
South Korea-based Alteogen has signed an exclusive licensing deal worth up to $365m with a global pharmaceutical company, granting worldwide rights to develop and commercialise a subcutaneous biologic product using its Hybrozyme technology.
In a May 2014 letter to Acura, FDA questioned the relevance of abuse of hydrocodone with acetaminophen products by nasal snorting after reviewing clinical and epidemiology data submitted
The company develops new therapies intended to improve outcomes in patients suffering from life-threatening diseases. La Jolla Research and Development vice-president and an inventor on the allowed patent
The title of the publication is "Encapsulated Cells Expressing a Chemotherapeutic Activating Enzyme Allow the Targeting of Subtoxic Chemotherapy and Are Safe and Efficacious: Data from Two Clinical